FIELD: pharmacology.
SUBSTANCE: recombinant multimeric scaffold based on FnIII domain of tenascin (Tn3), which specifically binds to TRAIL 2 receptor 2 (TRAIL R2), is proposed. In addition, an isolated nucleic acid molecule encoding a multimeric scaffold is considered; an expression vector; a host cell and a method for production of a recombinant multimeric scaffold. Also described: a pharmaceutical composition; a method for cancer symptoms prevention, treatment or reduction; a method for apoptosis induction in a cell and a method to alter the activity of a TRAIL R2-expression cell. The multimeric scaffold of the present invention has increased affinity for TRAIL R2, increased stability, and decreased immunogenicity.
EFFECT: possibility of compositions application in therapy and diagnosis of diseases associated with TRAIL R2.
32 cl, 25 tbl, 28 dwg, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD40L-SPECIFIC CARCASS STRUCTURES DERIVED FROM Tn3, AND METHODS FOR USE THEREOF | 2012 |
|
RU2704992C2 |
| INHIBITORS OF RECEPTORS OF TYPE 2 VESSEL ENDOTHELIUM GROWTH FACTOR | 2004 |
|
RU2402567C2 |
| NOVEL IL-17-BINDING COMPOUNDS AND THEIR MEDICINAL APPLICATION | 2010 |
|
RU2550272C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS | 2015 |
|
RU2699285C2 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
| ANTAGONISTS AND METHOD OF USING SAID ANTAGONISTS | 2005 |
|
RU2401842C2 |
| CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY | 2010 |
|
RU2573896C2 |
| METHOD OF IDENTIFYING HETEROMULTIMERIC MODIFIED UBIQUITIN PROTEINS POSSESSING ABILITY TO BIND WITH LIGANDS | 2010 |
|
RU2553333C2 |
